Does TRT really delay biochemical recurrence after radical prostatectomy (in selected patients)?

Some data presented a few weeks ago at the annual meeting of the European Association for Urology appear to have surprised not only the study’s authors, but pretty much everyone else as well. … READ MORE …

“Long-term” data on FLA in the treatment of localized prostate cancer

An important new paper in the Journal of Vascular and Interventional Radiology has just provided us with the first large set of data on the outcomes of men with prostate cancer treated with focal laser ablation (FLA). … READ MORE …

Wide uptake of active surveillance across VA medical system

A research letter in the Journal of the American Medical Association reports a major uptake in the application of active surveillance as a first-line form of management of prostate cancer across the Veterans Affairs health system here in the US since 2005. … READ MORE …

Short-term ADT for men on active surveillance?

One paper to be presented at the upcoming annual meeting of the American Urological Association (AUS) gives results from treatment with a 3-month dose of androgen deprivation therapy (ADT) for men with low-risk prostate cancer compared to standard active surveillance. … READ MORE …

Tookad-Soluble + VTP effective and safe in treatment of low-risk prostate cancer

Another new media report (based on data just published in Lancet Oncology) states that “vascular-targeted photodynamic therapy” or VTP in combination with an experimental drug called padeliporfin or WST11 can be used to successfully treat low-risk prostate cancer. … READ MORE …

PRIAS reports data from a 5,000+ patient active surveillance study

Data from a recent paper in European Urology has further confirmed the value of active surveillance as a first-line management option for men diagnosed with low-risk prostate cancer. It has also confirm recent guidance for when men on active surveillance actually need to be advised that treatment is probably wise. … READ MORE …

Just “delaying” surgery does increase risk … but it’s not active surveillance

A key question for men diagnosed with low-risk prostate cancer is always going to be whether, and for how long, they can defer treatment without increasing the risk that delayed treatment will be less effective (or riskier) in some ways. … READ MORE …